Cartesian Therapeutics (RNAC) Share-based Compensation (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.4 million, down 3.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (up 36.26% YoY), and the FY2025 annual result was $10.5 million, up 59.85% from the prior year.
• Share-based Compensation grew to $2.4 million in Q1 2026 per RNAC's latest filing, from $2.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.1 million in Q4 2023 and troughed at $1.4 million in Q1 2024.
• A 5-year average of $3.1 million and a median of $2.4 million in 2026 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 521.44% in 2023, then tumbled 86.81% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $2.3 million in 2022, then surged by 521.44% to $14.1 million in 2023, then plunged by 86.81% to $1.9 million in 2024, then grew by 14.96% to $2.1 million in 2025, then increased by 13.01% to $2.4 million in 2026.
• Business Quant data shows RNAC's Share-based Compensation at $2.4 million in Q1 2026, $2.1 million in Q4 2025, and $2.6 million in Q3 2025.